参考文献
［1］温瓦尼.放射性药物手册.夏振民，等译.北京：中国原子能出版社.2000.
［2］顾慰萍，朱霖.中国放射性药物发展战略研究.北京：中国原子能出版社.2006.
［3］韩全胜，陈铁光，黄能武.放射性核素治疗的发展和现状.标记免疫分析与临床.2013.6：463-466.
［4］George Sgouros，Lisa Bodei，Michael R McDevitt.Radiopharmaceutical therapy in cancer：clinical advances and challenges.Nat Rev Drug Discov.2020；19（9）：589-608.
［5］鲍世宽.放射性药物对患者产生的辐射剂量.北京：中国原子能出版社.1991.
［6］Cathy S Cutler，？Elizabeth A Bailey，Vijay Kumar.Global Issues of Radiopharmaceutical Access and Availability：a Nuclear Medicine Global Initiative Project.J NuclMed.2020.
［7］王荣福，安锐.核医学.第9版.北京：人民卫生出版社.2018.
［8］中华医学会核医学分会转移性骨肿瘤治疗工作委员会.氯化锶［89Sr］治疗转移性骨肿瘤专家共识（2017年版）.中华核医学与分子影像杂志.2018.38（6）：412-415.
［9］Marie ØbroFosbøl，Peter MeidahlPetersen，Andreas Kjaer.223 Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer：Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity.J Nucl Med.2018.59（4）：596-602.
［10］Pradeep Thapa，DilipNikam，Tapas Das.Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.J Nucl Med.2015.56（10）：1513-1519.
［11］Ana M Denis-Bacelar，Sarah J Chittenden，David P Dearnaley.Phase I/Ⅱ trials of 186 Re-HEDP in metastatic castration-resistant prostate cancer：post-hoc analysis of the impact of administered activity and dosimetry on survival.Eur J Nucl Med Mol Imaging.2017.44（4）：620-629.
［12］Federica Orsini，Federica Guidoccio，Sara Mazzarri.Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer：a retrospective analysis.J Nucl Med.2012.53（8）：1330-1331.
［13］桑士标，李清茹，吴翼伟.放射性核素治疗骨转移癌应注意的几个问题.苏州大学学报（医学版）.2004.6：964-965.
［14］张伟军，王兆武，刘枫.放射治疗与放射性同位素治疗骨转移癌疗效分析.广州医药.1999.5：3-5.
［15］林祥通.关于放射性核素治疗骨转移癌所致疼痛的疗效评估.中华核医学杂志.1995.2.(https://www.daowen.com)
［16］匡安仁.131I治疗分化型甲状腺癌.北京：人民卫生出版社.2013.
［17］F.Grunwald，H.-J.Bier.甲状腺癌.李宁译.北京：人民卫生出版社.2000.
［18］陈立波，丁勇，关海霞.中国临床肿瘤学会（CSCO）持续/复发及转移性分化型甲状腺癌诊疗指南-2019.肿瘤预防与治疗.2019.12：1051-1080.
［19］Jingjing Zhang，Hao Wang，Orit Jacobson.Safety，Pharmacokinetics，and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.J Nucl Med.2018.59（11）：1699-1705.
［20］Hao Wang，Yuejuan Cheng，Jingjing Zhang.Response to Single Low-dose 177 Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm：A Prospective Pilot Study.Theranostics.2018.8（12）：3308-3316.
［21］E Seregni，M Maccauro，C Chiesa.Treatment with tandem［90Y］DOTA-TATE and［177Lu］DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.Eur J Nucl Med Mol Imaging.2014.41（2）：223-30.
［22］Qingxing Liu，Jie Zang，Huimin Sui.Peptide Receptor Radionuclide Therapy of Late-stage Neuroendocrine Tumor Patients with Multiple Cycles of 177 Lu-DOTA-EB-TATE.J Nucl Med.2020.Aug 21.
［23］Thorsten Derlin，Sebastian Schmuck.［177Lu］-PSMA-617 radionuclide therapy in patients with metastatic castrationresistant prostate cancer.Lancet Oncol.2018 Aug；19（8）：e372.
［24］Matthias M Heck，Robert Tauber，Sebastian Schwaiger.Treatment Outcome，Toxicity，and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.Eur Urol.2019.75（6）：920-926.
［25］Robert Seifert，Konstantin Seitzer，Ken Herrmann.Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177 Lu-PSMA-617 Radioligand Therapy.Theranostics.2020.10（17）：7812-7820.
［26］Jie Zang，Xinrong Fan，Hao Wang.First-in-human study of 177 Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.Eur J Nucl Med Mol Imaging.2019.46（1）：148-158.
［27］Daniel A Pryma，Bennett B Chin，Richard B Noto.Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.J Nucl Med.2019.60（5）：623-630.
［28］Matthew P Thorpe，Ari Kane，Jason Zhu.Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.J Clin Endocrinol Metab.2020.105（3）：dgz074.
［29］Gonca Kara Gedik，Cornelis A Hoefnagel，Evert Bais.131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.Eur J Nucl Med Mol Imaging.2008.35（4）：725-733.
［30］TeikHin Tan，Teck Huat Wong，Siti Zarina Amir Hassan.Unusual Bone Superscan，MIBG Superscan，and 68Ga DOTATATE PET/CT in Metastatic Pheochromocytoma.Clin Nucl Med.2015.40（11）：867-868.